Table 2.
Variables Associated With Primary Outcome Among PWID With Complicated S. aureus Bacteremia
| Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P Value | OR | 95% CI | P Value | |
| Patient demographicsa | ||||||
| Insurance | ||||||
| ȃManaged care | 1.0 | Reference | 1 | |||
| ȃMedicaid | NS | (reference) | NS | |||
| ȃMedicare | 3.9 | (0.8–18.8) | 0.09 | (1.1–33.0) | .04 | |
| ȃSelf-pay | NS | 5.9 | NS | |||
| Inpatient care | ||||||
| OUD treatment | ||||||
| ȃNone | 1 | |||||
| ȃBuprenorphine | (reference) | (0.2, 1.0) | .04 | … | … | NS |
| ȃMethadone | .04 | NS | ||||
| Addiction medicine consult | 0.4 | (0.2–0.8) | .01 | … | … | NS |
| Duration of IV antibiotics before Discharge: | ||||||
| ȃBacteremic at discharge; | 4.5 | (1.0–20.8) | .05.01 | … | … | … |
| ȃ1-9 days effective IV abx | 0.1 | (0.02–0.5) | <.001 | |||
| ȃ10+ days effective IV abx | 0.1 | (0.01–0.3) | <.001 | |||
| ȃCompleted Inpatient IV abx | 0.03 | (0.01–0.1) | ||||
| Elixhauser comorbiditiesa | ||||||
| Fluid and electrolyte disorders | 0.5 | (0.2–0.9) | .03 | 0.4 | (0.2–1.0) | .06 |
| Paraplegia | 6.9 | (2.3–20.5) | <.001 | 7.8 | (2.1–28.6) | .002 |
| Infection characteristicsa | ||||||
| Septic arthritis | 2.4 | (1.2–5.1) | .02 | 2.3 | (1.0–5.4) | .06 |
| Antibiotic treatment group | ||||||
| Completed inpatient IV | 1.0 (reference) | 1.0 (reference) | … | … | ||
| Partial IV, partial oral | 1.3 | (0.5–3.1) | .6 | - | - | NS |
| Partial IV, no oral | 6.7 | (2.8–16.0) | <.001 | 7.9 | (2.9–21.6) | <.001 |
Abbreviations: abx, antibiotics; CI, confidence interval; IV, intravenous; NS, not significant; OR, oods ratio; OUD, opioid use disorder; PWID, persons who inject drugs; S. aureus, Staphylococcus aureus.
Only variables that were statistically significant in univariate analysis are listed; statistical significance is included at the 5% level.